CATX
Perspective Therapeutics Inc
AMEX · Biotechnology
$4.71
+0.08 (+1.73%)
Open$4.72
Previous Close$4.63
Day High$4.78
Day Low$4.45
52W High$6.16
52W Low$1.60
Volume—
Avg Volume12.97M
Market Cap536.54M
P/E Ratio—
EPS$-1.46
SectorBiotechnology
Analyst Ratings
Strong Buy
19 analysts
Price Target
+317.6% upside
Current
$4.71
$4.71
Target
$19.67
$19.67
$12.33
$19.67 avg
$23.14
Key Financials
| FY 2026 | FY 2025 | FY 2025 | |
|---|---|---|---|
| Revenue | 2.57M | 5.02M | 71.95M |
| Net Income | -140,182,672 | -246,174,448 | -11,935,296 |
| Profit Margin | -5,452.5% | -5,179.9% | -16.6% |
| EBITDA | -156,620,475 | -290,320,880 | -19,768,936 |
| Free Cash Flow | — | — | -4,863,546 |
| Rev Growth | -48.8% | -48.8% | -9.3% |
| Debt/Equity | 0.01 | 0.01 | 0.54 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |